Saltanat Jetybayeva

Saltanat Jetybayeva

Auto-generated profile, based on publicly available information

Saltanat Jetybayeva

Cardiology Department №1, “University Medical Center” Corporate Fund, Astana, Kazakhstan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in BULLETIN OF SURGERY IN KAZAKHSTAN
Verified
Journal Article
Closed access
ASAliya Sailybayeva
Aliya Sailybayeva
AKAlmagul Kushugulova
Almagul Kushugulova
SJS Jetybayeva
S Jetybayeva
ATA Tauekelova
A Tauekelova
ZDZ Duisenbina
Z Duisenbina
AZA Zholdybaeva
A Zholdybaeva
Background. Heart failure is one of the most significant medical problems of our time, which is associated with the increase in the prevalence of the disease over the past decade. The six-minute walk test is a simple, accessible, and informative tool for assessing the physical activity of patients with heart failure. The test results correlate with peak oxygen consumption and can be used to monitor the effectiveness of rehabilitation programs. The aim of the study is to evaluate the effectiveness of the six-minute walk test as a tool for measuring the level of physical activity and functional status in patients with heart failure, and to determine its correlation with clinical indicators and quality of life in this category of patients. Materials and methods. In this study, conducted on the basis of the UMC "Heart Center" Astana, Kazakhstan, private institution "National Laboratory Astana ", data of patients with heart failure of class I-IV according to a special classification were analyzed. The main objective of the study was to evaluate the effectiveness of the test as a tool for monitoring physical activity and functional status of patients. Results. The results showed that the test is a reliable method for assessing the dynamics of physical capabilities and can be used to individualize rehabilitation programs. Conclusion. The 6MWT remains an important component of clinical practice, helping to optimize functional outcomes and improve the quality of life of patients with heart failure.

30 June 2025 in Наука и здравоохранение
Verified
Journal Article
Open access
ASAliya Sailybayeva
Aliya Sailybayeva
ASA.I. Sailybaeva
A.I. Sailybaeva
GKG.A. Kabduyeva
G.A. Kabduyeva
SJS.K. Jetybayeva
S.K. Jetybayeva
ATA.T. Tauekelova
A.T. Tauekelova
AKAlmagul Kushugulova
Almagul Kushugulova
Background. Chronic heart failure is a growing global health challenge, particularly in Kazakhstan, where demographic changes and rising numbers of comorbidities are worsening the burden. However, data on CHF prevalence, diagnosis and healthcare resource distribution in the regions remain limited. This study aims to assess and compare the epidemiological trends, regional disparities and healthcare system capacity of CHF in Kazakhstan based on recent national data. Materials and methods. A retrospective analysis was conducted using national healthcare records from 2023–2024, including chronic heart failure prevalence, new diagnoses, stage distribution, regional healthcare resources and surgical interventions of patients. The Gini index was used to evaluate regional disparities, along with other statistical analyses. Results. In 2024, 87,260 patients were examined, with a 19% increase from 2023. Of 12,874 new cases, 75.6% were identified in early stages (A and B), suggesting progress in early detection. However, regional disparities were severe, with Gini indices for ProBNP testing and echocardiography at 0.556 and 0.480, respectively. High-resource areas like Almaty contrasted sharply with under-resourced regions such as Mangystau and Kyzylorda wtih heart transplants being declined, while LVAD usage increasing which reflects evolving treatment patterns amid limited donor availability. Conclusion. Chronic heart failure is increasing in Kazakhstan amid significant regional and systemic inequalities in care. Targeted interventions with improved diagnostic access, equitable resource allocation, and national policy reform are urgently needed to manage the growing burden and improve outcomes of patients across the country. Введение. Хроническая сердечная недостаточность становится растущей проблемой общественного здравоохранения во всем мире, особенно в Казахстане, где демографические изменения и рост сопутствующих заболеваний усугубляют бремя. Однако данные о распространенности ХСН, диагностике и распределении ресурсов здравоохранения в регионе остаются ограниченными. Цель.Оценка эпидемиологических тенденций, географических различий и возможностей системы здравоохранения, связанных с ХСН в Казахстане, на основе последних национальных данных. Материалы и методы. Ретроспективный анализ проводился с использованием национальных записей здравоохранения за 2023–2024 годы. Данные включали распространенность ХСН, новые диагнозы, распределение стадий, региональные ресурсы здравоохранения и хирургические вмешательства. Для оценки региональных различий использовались показатели неравенства, такие как индекс Джини. Результаты. В 2024 году было обследовано 87 260 пациентов с ХСН, что на 19% больше, чем в 2023 году. Из 12 874 новых случаев 75,6% были выявлены на ранних стадиях (A и B), что свидетельствует о прогрессе в раннем выявлении. Однако региональные различия в лечении были резкими: индексы Джини для тестирования ProBNP и эхокардиографии составили 0,556 и 0,480 соответственно. Регионы с высоким уровнем ресурсов, такие как Алматы, резко контрастировали с регионами с низким уровнем ресурсов, такими как Мангистауская и Кызылординская области. Количество трансплантаций сердца сократилось, в то время как использование LVAD увеличилось, что отражает меняющиеся модели лечения на фоне ограниченного количества доноров. Заключение. ХСН растет в Казахстане на фоне значительного регионального и системного неравенства в лечении. Целевые вмешательства — улучшение диагностического доступа, справедливое распределение ресурсов и реформа национальной политики — срочно необходимы для управления растущим бременем и улучшения результатов по всей стране. Кіріспе.Созылмалыжүрекжеткіліксіздігібүкіләлемде, әсіреседемографиялықөзгерістерменқатаржүретінаурулардыңөсуіауыртпалықтыкүшейтетінҚазақстандақоғамдықденсаулықтыалаңдатыпотыр. Дегенмен, аймақтааурудыңтаралуы, диагностикасыжәнеденсаулықсақтауресурстарынбөлутуралыдеректершектеуліболыпқалабереді....

30 June 2025 in BULLETIN OF SURGERY IN KAZAKHSTAN
Verified
Journal Article
Closed access
BMBekbosynova M
Bekbosynova M
AKAlmagul Kushugulova
Almagul Kushugulova
JSJetybayeva S
Jetybayeva S
TSTaukelova S
Taukelova S
MAMyrzakhmetova A
Myrzakhmetova A
TSTleubaeva S
Tleubaeva S
Background. With the aging population, the number of people with frailty syndromes receiving treatment for cardiovascular diseases is increasing. Diagnosis of frailty syndrome prior to complex and invasive procedures may have implications for prognosis and recovery. The aim of this study was to assess the prevalence of frailty and describe its associated clinical course and outcomes in patients referred for cardiac surgery. Materials and methods. A prospective cohort of patients over 18 years of age referred for cardiac surgery at the non-profit joint-stock company "National Scientific Cardiac Surgery Center" in Astana, Department of Cardiac Surgery, from November 2022 to April 2023, was examined before surgery for the presence of frailty, determined by the deficit accumulation model scale. The analysis included clinical, anamnestic, instrumental and laboratory data, surgical results, development of complications and adverse outcomes in the perioperative period. Statistical processing of the study results was performed. Results. Fragility was detected in 32% of patients before open cardiac surgery. Differences were revealed in the intraoperative and early postoperative periods: rhythm disturbances developed more often (20.8% versus 3.9%), transient ischemic attack / acute cerebrovascular accident of the ischemic type (8.3% versus 3.9%), hydrothorax (31.25% versus 11.7% and 5.8%), implantation of extracorporeal membrane oxygenation (12.5 % versus 3.9%) .In the group of patients with frailty, two fatal outcomes were recorded. Conclusions. Frailty was observed in 32% of patients undergoing cardiac surgery and was associated with higher risk of morbidity and increased healthcare utilization.

30 December 2024 in Наука и здравоохранение
Verified
Journal Article
Open access
MBM.S. Bekbosynova
M.S. Bekbosynova
SJS.K. Jetybaeva
S.K. Jetybaeva
BABaurzhan Aipov
Baurzhan Aipov
KNK.R. Nurlan
K.R. Nurlan
ASA.I. Sailybaeva
A.I. Sailybaeva
AKAlmagul Kushugulova
Almagul Kushugulova
Background. Chronic heart failure (CHF) is a global health issue with high mortality rates. According to statistical data, in Kazakhstan, 4.7% of the population suffers from CHF, which amounts to approximately 320,000 people. In the United States, 6.7 million individuals are affected, with projections rising to 8.5 million by 2030. Despite advancements in treatment, mortality rates remain high. Recent studies highlight the role of gut microbiota in systemic inflammation, a key factor in cardiovascular diseases. Exploring the gut microbiota offers a novel perspective for understanding CHF pathogenesis and potential therapeutic interventions. Aim. The review aims to explore the role of gut microbiota in the development and progression of CHF and examine new methods to improve the clinical status of patients through gut microbiota modulation. Search strategy. A literature review was conducted using PubMed, Medline, Cochrane Central register of Controlled Trials database, Web of Science, Scopus, https://elibrary.ru, and Google Scholar over the past 10 years, providing information on the role of the gut microbiota in the development and progression of CHF. The review includes works published in Russian and English Results. Disruption of the intestinal barrier allows endotoxins and microbial metabolites to enter systemic circulation, triggering systemic inflammation and endothelial dysfunction, exacerbating CHF. Gut hypoperfusion and increased permeability further contribute to the disease's progression. Microbial metabolites, such as trimethylamine-N-oxide (TMAO) and short-chain fatty acids (SCFAs), influence systemic inflammation. Elevated TMAO levels are linked to cardiovascular events, while SCFAs have protective effects but are reduced in CHF patients. Gut dysbiosis is prevalent in CHF, marked by altered microbiota composition, including decreased beneficial bacteria and increased pathogenic species. These changes correlate with systemic inflammation and disease severity. Conclusions.The gut microbiota significantly impacts CHF pathogenesis through its influence on systemic inflammation and metabolic pathways. Modulating gut microbiota presents promising therapeutic opportunities, including dietary adjustments, probiotics, prebiotics, and fecal microbiota transplantation. Further research is essential to optimize interventions and explore the gut-heart axis's role in CHF progression and comorbidities. Введение. Хроническая сердечная недостаточность (ХСН) представляет собой глобальную проблему здравоохранения с высокой смертностью. Согласно статистическим данным в Казахстане 4,7 % населения страдает от ХСН, что составляет примерно 320 тыс. чел. В США страдают ХСН 6,7 млн человек, к 2030 году прогнозируется увеличение числа пациентов до 8,5 млн. В целом глобальная распространенность ХСН варьируется от 100 до 900 случаев на 100 тыс. человеко-лет в зависимости от используемых диагностических критериев и исследуемой популяции. Несмотря на достижения в лечении ХСН, сохраняются высокая частота госпитализаций и смертность. Новые исследования уделяют внимание роли кишечной микробиоты в развитии системного воспаления, которое играет важную роль в патогенезе сердечно-сосудистых заболеваний. Изучение микробиоты открывает новые перспективы в понимании патогенеза ХСН и разработке терапевтических подходов. Цель исследования. Исследовать роль кишечной микробиоты в развитии и прогрессировании ХСН, а также рассмотреть новые методы коррекции клинического состояния пациентов путем модуляции микробиоты. Стратегия поиска. Поиск литературы проводился с использованием ресурсов PubMed, Medline, Центрального реестра контролируемых испытаний Cochrane, Web of Science, Scopus, https://elibrary.ru и Google Scholar за последние 10 лет, предоставляющий информацию о роли микробиоты кишечника в развитии и прогрессировании ХСН. Обзор включает работы, опубликованные на русском и английском языках. Результаты. Нарушение барьерной функции кишечника способствует проникновению эндотоксинов и микробных метаболитов в системный кровоток, что вызывает системное воспаление и эндотелиальную дисфункцию, ухудшающую течение ХСН. Гипоперфузия кишечника и увеличение его проницаемости усугубляют прогрессирование заболевания. Метаболиты микробиоты, такие как триметиламин-N-оксид (ТМАО) и короткоцепочечные жирные кислоты (КЦЖК), участвуют в развитии системного воспаления. Высокий...

18 September 2026 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
ATAinur Tauekelova
Ainur Tauekelova
BKBakhytnur Karipova
Bakhytnur Karipova
AZAida Zholdybaeva
Aida Zholdybaeva
SKSadyk Khamitov
Sadyk Khamitov
SJSaltanat Jetybayeva
Saltanat Jetybayeva
AAAruzhan Asanova
Aruzhan Asanova
Background: Evidence describing the longitudinal effectiveness and tolerability of tirzepatide in adults with obesity and heart failure with preserved ejection fraction (HFpEF) remains limited, particularly from prospective cohorts with repeated cardiometabolic assessments. This study evaluated longitudinal changes in weight, metabolic health, and treatment-emergent symptoms during tirzepatide therapy in a Kazakhstan cohort with obesity and HFpEF. Methods: We conducted a preliminary analysis of the tirzepatide-treated cohort enrolled at one center within a broader prospective interventional study. The present analysis included adults with obesity and HFpEF who received once-weekly tirzepatide according to a prospectively defined treatment protocol. Participants underwent scheduled assessments from baseline through Week 41. Longitudinal changes in anthropometric, metabolic, inflammatory, renal, and body composition outcomes were analyzed using linear mixed-effects models. Individual treatment-emergent symptoms were summarized descriptively, while longitudinal regression models were used for aggregated adverse-event outcomes and symptom burden. Complete-case and exploratory predictor analyses were performed as sensitivity analyses. Results: Twenty-four participants with obesity and HFpEF contributed longitudinal observations, including 16 with mature Week-41 follow-up. Tirzepatide treatment was associated with significant reductions in body weight, BMI, waist circumference, fasting glucose, triglycerides, and selected inflammatory markers over time. Mean percentage weight loss at Week 41 was 17.2±8.1%, corresponding to 18.7±7.0 kg. Among the 16 participants with paired baseline and Week-41 measurements, all achieved ≥5% weight loss, while 87.5%, 50.0%, and 25.0% achieved ≥10%, ≥15%, and ≥20% weight loss, respectively. Gastrointestinal symptoms were reported in 25.0% of participants, with nausea (20.8%) and vomiting (12.5%) being the most frequently recorded. No serious adverse events were observed during the study period. No statistically significant association was detected between gastrointestinal symptom occurrence or burden and longitudinal weight loss; however, these analyses were exploratory given the small number of gastrointestinal events. Conclusions: In this preliminary analysis of a prospective tirzepatide-treated cohort of adults with obesity and HFpEF from Kazakhstan, tirzepatide was associated with substantial and sustained weight loss accompanied by favorable cardiometabolic changes. Gastrointestinal symptoms were reported in a minority of participants, although their severity was not formally graded. These findings should be interpreted within the specific clinical context of obesity with concomitant HFpEF.

1 October 2025 in BULLETIN OF SURGERY IN KAZAKHSTAN
Verified
Journal Article
Closed access
BABaurzhan Aipov
Baurzhan Aipov
KNK Nurlan
K Nurlan
ZAZ Aldanysh
Z Aldanysh
ATA Taukelova
A Taukelova
SJS Jetybayeva
S Jetybayeva
AKAlmagul Kushugulova
Almagul Kushugulova
Background. The objective of this study was to investigate the prevalence of periodontitis in patients with chronic heart failure, as well as to characterize the microbiological profile of periodontitis across different chronic heart failure phenotypes. The objective is to analyze the link between oral health and heart disease. Materials and Methods. A cohort of 98 chronic heart failure patients (mean age 62.22 ± 8.62 years, 69 men) was assessed through comprehensive cardiological and periodontal examinations. Patients were categorized into heart failure with reduced ejection fraction, mildly reduced ejection fraction, and preserved ejection fraction. Periodontal parameters, including probing pocket depth, clinical attachment loss, and bleeding on probing were evaluated. Microbiological and statistical analyses were conducted. Results. Severe periodontitis (Stage C) was identified in 30% of patients, while 48% had moderate periodontitis (Stage B). Patients with chronic heart failure with reduced ejection fraction exhibited the highest prevalence of severe periodontitis, with a significant correlation between increased probing pocket depth and reduced ejection fraction. Candida species abundance was associated with lower ejection fraction (p≤0.0Y) and advanced periodontitis (p≤0.0X). Elevated NT-proBNP levels (1121.00–7611.00 pg/mL) correlated with Streptococcus mitis prevalence, while C-reactive protein levels (up to 2.35 mg/dL) were highest in patients with Klebsiella pneumoniae. Conclusion. The study highlights a strong association between periodontal disease, microbial dysbiosis, and CHF. Findings suggest that oral microbial imbalances, particularly involving Candida, Streptococcus mitis, and Klebsiella pneumoniae, contribute to systemic inflammation and cardiovascular complications.